12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Company News  |  Other News

AMAG Pharmaceuticals hematology news

Chairman Michael Narachi said it was time to shift AMAG's focus away from a potential sale of the company in order to grow sales of anemia drug Feraheme ferumoxytol and pursue "business development opportunities." The announcement was concurrent with the hiring of William...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >